June 18, 2021
Business News

Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer


TOKYO & MUNICH & BASKING RIDGE, N.J.–()–New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.

These preliminary data from the TNBC cohort of the TROPION-PanTumor01 phase 1 study were presented as a late-breaking mini oral presentation (Abstract #LBA4) at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress (#ESMOBreast21).

TNBC accounts for approximately 10 to 15% of breast cancer cases and is…



Click here to view the original article.

Related Posts

You might also like ...

Dan Stahlschmidt Joins Academy Securities as Managing Director, Head of Equity Capital Markets
AON Splash Image
eCommerce Funding and Payments Leader Payability Hires VP of Growth Marketing
AON Splash Image
Arkema Announces a New Breakthrough Range of Renewable PVDF Grades for Lithium-Ion Batteries